ATLANTA, Jan. 28 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., Chief Executive Officer and President, will present a corporate update at the Eleventh Annual BIO CEO & Investor Conference 2009, held at the Waldorf-Astoria Hotel, in New York, on February 9-10, 2009.
The BIO CEO & Investor Conference is the preeminent gathering of cutting edge biotechnology companies, represented by senior executives, presenting their achievements to institutional investors, industry analysts and portfolio senior executives. Presenting companies were selected through a competitive screening process with a focus on their potential to deliver near-term clinical accomplishments in areas of unmet medical need. The expected attendance at the conference will include representatives from nearly 80 investment firms with a specific interest in life science companies.
Dr. McNally will present an overview of GeoVax's vaccine technology and will report the latest progress on the Company's Phase 2a preventative human vaccine trial and plans for upcoming therapeutic human vaccine trials. Dr. McNally also plans to meet one-on-one with current and prospective GeoVax investors, analysts, investment bankers and other potential Company partners.
"Having met significant milestones entering Phase 2a human trials with our
highly promising HIV-1/AIDS vaccines and with our plans to launch our
therapeutic human trials in the near future, the time has arrived for the
Biotech sector and its respective investment audience to learn about our
progress. We feel privileged to be among a select group of biotech companies
showcasing our technologies to an elite group of interested investment
|SOURCE GeoVax Labs, Inc.|
Copyright©2009 PR Newswire.
All rights reserved